Skip to main content

Errata - English

PDF CSV October 18, 2023 through October 18, 2025 All Errata for USP–NF How to use
Enter the title of the monograph
Monograph Title Section Source Publication Page Number Errata Official Date Target Errata Print Publication Target Online Fix Publication Description
HYOSCYAMINE SULFATE USP Reference standards <11> USP37–NF32 3293 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 2 of USP Hyoscyamine Related Compound A RS: Change
(1R,3R,5S)-8-azabicyclo[3.2.1]oct-3-yl(2S)-3-hydroxy-2-phenylpropanoate.
to:
(1R,3r,5S)-8-Azabicyclo[3.2.1]oct-3-yl(2S)-3-hydroxy-2-phenylpropanoate sulfate (2:1).
METHOTREXATE IMPURITIES/Organic Impurities/Procedure 1: Related Compounds USP37–NF32 3762 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Standard solution A: Change
0.1 μg/mL of USP Methotrexate RS in Solution A, from the Standard stock solution
to:
0.1 µg/mL of USP Methotrexate RS in Solution A, from Standard stock solution A
PACLITAXEL Related compounds/Test 2 (for Material Labeled as Produced by a Semisynthetic Process) USP37–NF32 4163 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 6 after table in Chromatographic system: Change
the relative standard deviation for replicate injections is not more than 2.0%.
to:
the relative standard deviation for replicate injections is not more than 2.0% for the paclitaxel peak.
PANCURONIUM BROMIDE ASSAY/Procedure/Chromatographic system USP37–NF32 4176 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Column: Change
4.6-mm × 250-cm; 5-µm packing L1
to:
4.6-mm × 25-cm; 5-µm packing L1
POTASSIUM BITARTRATE IDENTIFICATION USP37–NF32 4346 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Change
C. Identification Tests—General, Tartrate <191>
to:
C. Identification Tests—General, Tartrate <191>: Meets the requirements
AND
Delete subsections:
Sample solution: 1 in 10 solution
Acceptance criteria: Meets the requirements
POTASSIUM SODIUM TARTRATE Identification/C: USP37–NF32 4369 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Change
A solution (1 in 10) responds to the tests for Tartrate <191>.
to:
Responds to the tests for Tartrate <191>.
TERAZOSIN TABLETS PERFORMANCE TESTS/Dissolution <711> USP37–NF32 4874 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 10 of Analysis: Change
Mr2 = molecular weight of terazosin hydrochloride dihydrate, 459.92
to:
Mr2 = molecular weight of terazosin hydrochloride, 423.89
TETRACAINE OINTMENT Assay USP37–NF32 4891 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 7 of Procedure: Change
(264.37/300.83)(C)(AU / AS)
to:
(264.36/300.82)(C)(AU / AS)
VALSARTAN TABLETS PERFORMANCE TESTS/Dissolution <711> USP37–NF32 5116 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Medium: Change
pH 6.8 phosphate buffer; 1000 mL, degassed
to:
pH 6.8 phosphate buffer prepared as follows. Dissolve 6.805 g of monobasic potassium phosphate and 0.896 g of sodium hydroxide in and dilute with water to 1000 mL. Adjust with 0.2 M sodium hydroxide or 1 M… Read More
ZIPRASIDONE HYDROCHLORIDE IMPURITIES/Limit of Tetrahydrofuran USP37–NF32 5219 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Standard solution: Change
0.05 mg/mL of USP Ziprasidone Hydrochloride RS in dimethyl sulfoxide
to:
0.05 mg/mL of tetrahydrofuran in dimethyl sulfoxide
RED CLOVER TABLETS SPECIFIC TESTS/Microbial Enumeration Tests <2021> USP37–NF32 5526 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 4: Change
NLT 103 cfu/g.
to:
NMT 103 cfu/g.
EXTENDED PHENYTOIN SODIUM CAPSULES IDENTIFICATION/A. Infrared Absorption—General <197> First Supplement to USP37–NF32 6681 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Sample: Change
6 mg/mL of phenytoin sodium in water from a suitable number of Capsules prepared as follows. Nominally transfer 300 mg of the powder into 50 mL of water in a separator.
to:
300 mg of phenytoin sodium from the contents of Capsules in 50 mL of water in a… Read More
GLYCERYL BEHENATE ASSAY/Procedure/Chromatographic system Second Supplement to USP37–NF32 7075 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Column: Change
7.0-mm × 60-cm; 5-µm packing L21
[Note—Two 7.0-mm × 30-cm L21 columns
to:
7.5-mm × 60-cm; 5-µm 100-Å packing L21
[Note—Two 7.5-mm × 30-cm L21 columns
RISPERIDONE ADDITIONAL REQUIREMENTS/USP Reference Standards <11> Second Supplement to USP37–NF32 7240 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 2 of USP Risperidone Related Compound G RS: Change
3-[2-[4-(4-Fluoro-2-hydroxybenzoyl)piperidin-1-yl]ethyl]-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one.
C23H28FN3O3 413.49
to:
3-[2-[4-(4-… Read More
AMIODARONE HYDROCHLORIDE ORGANIC IMPURITIES/Procedure 1/Chromatographic system USP38–NF33 2198 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Adsorbent: Change
0.5-mm layer of chromatographic silica gel and fluorescent indicator with maximum absorbance at 254 nm
to:
Suitable layer of chromatographic silica gel and fluorescent indicator with maximum absorbance at 254 nm
ATROPINE SULFATE ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP38–NF33 2325 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 2 of USP Hyoscyamine Related Compound A RS: Change
Norhyoscyamine sulfate; (1R,3r,5S)-8-azabicyclo [3.2.1]oct-3-yl(2S)-3-hydroxy-2-phenylpropanoate.C16H21NO3 275.34
to:
Norhyoscyamine sulfate; (1R,3r,5… Read More
BUTABARBITAL SODIUM ORAL SOLUTION ASSAY/Procedure USP38–NF33 2500 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 17 of Analysis: Change
CU = nominal concentration of butabarbital sodium in the Sample solution (µg/mL)
to:
CU = nominal concentration of butabarbital sodium in the Sample solution (mg/mL)
BUTABARBITAL SODIUM TABLETS PERFORMANCE TESTS/Uniformity of Dosage Units <905>/Procedure for content uniformity USP38–NF33 2501 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 18 of Analysis: Change
CU = nominal concentration of butabarbital sodium in the Sample solution
to:
CU = nominal concentration of butabarbital sodium in the Sample solution (mg/mL)
CAFFEINE CITRATE INJECTION ASSAY/Procedure USP38–NF33 2520 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 5 of Analysis: Change
Result = (rU/rS) × CS × (Mr1/Mr2) × 100
to:
Result = (rU/rS) × C Read More
CAFFEINE CITRATE ORAL SOLUTION ASSAY/Procedure USP38–NF33 2521 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 5 of Analysis: Change
Result = (rU/rS) × CS × (Mr1/Mr2) × 100
to:
Result = (rU/rS) × C Read More
CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE TABLETS ASSAY/Procedure USP38–NF33 2752 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Buffer: Change
0.20 sodium hydroxide
to:
0.20 N sodium hydroxide
CITRIC ACID, MAGNESIUM OXIDE, AND SODIUM CARBONATE IRRIGATION ASSAY/Citric Acid USP38–NF33 2844 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 16 of Analysis: Change
CU = nominal concentration of citric acid monohydrate in the Assay preparation for citric acid/citrate assay (units/mL)
to:
CU = nominal concentration of citric acid monohydrate in the Assay… Read More
ESCITALOPRAM TABLETS PERFORMANCE TESTS/Dissolution <711>/Test 2 USP38–NF33 3364 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 13 of Analysis: Change
Mr2 = molecular weight of escitalopram oxalate, 405.30
to:
Mr2 = molecular weight of escitalopram oxalate, 414.43
MESALAMINE RECTAL SUSPENSION OTHER COMPONENTS/Content of Sodium Benzoate (if present) USP38–NF33 4270 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 5 of Analysis: Change
Result = (rU/rS) × CS × (10/W) × 100
to:
Result = (rU/rS) × CS × (10/W)
PAROXETINE HYDROCHLORIDE IMPURITIES/Limit of 1-Methyl-4-(p-fluorophenyl)-1,2,3,6-tetrahydropyridine USP38–NF33 4765 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Standard solution: Change
42 mg/mL
to:
42 ng/mL
PAROXETINE HYDROCHLORIDE ADDITIONAL REQUIREMENTS/USP Reference Standards <11> USP38–NF33 4765 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Lines 4 and 7 of USP Paroxetine System Suitability Mixture A RS: Change
hydrochloride (3 S-trans)
to:
hydrochloride (3S-trans)
VALSARTAN AND HYDROCHLOROTHIAZIDE TABLETS ADDITIONAL REQUIREMENTS/USP Reference Standards <11> Revision Bulletin (Official April 01, 2014) Online 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 2 of USP Valsartan Related Compound B RS: Change
(S-N-Butyryl-N-([2′-(1H-tetrazole-5-yl)biphen-4-yl]methyl)-valine.
to:
N-Butyryl-N-{[2′-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine.
CIPROFLOXACIN EXTENDED-RELEASE TABLETS ASSAY/Procedure Revision Bulletin (Official October 01, 2014) Online 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 17 of Analysis: Change
Mr2 = molecular weight of ciprofloxacin hydrochloride, 367.81
to:
Mr2 = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81
CIPROFLOXACIN EXTENDED-RELEASE TABLETS PERFORMANCE TESTS/Dissolution <711> Revision Bulletin (Official October 01, 2014) Online 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 13 of Analysis in Test 1: Change
Mr2 = molecular weight of ciprofloxacin hydrochloride, 367.81
to:
Mr2 = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81
AND
Line 12 of Analysis in Test… Read More
CIPROFLOXACIN EXTENDED-RELEASE TABLETS IMPURITIES/Organic Impurities Revision Bulletin (Official October 01, 2014) Online 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Line 16 of Analysis: Change
Mr2 = molecular weight of ciprofloxacin hydrochloride, 367.81
to:
Mr2 = molecular weight of anhydrous ciprofloxacin hydrochloride, 367.81
AND
Line 14 of the second Calculate statement in Analysis… Read More
BUPROPION HYDROCHLORIDE EXTENDED-RELEASE TABLETS IMPURITIES/Organic Impurities Revision Bulletin (Official October 01, 2014) Online 1-Feb-2015 USP39–NF34 Second Supplement to USP38–NF33 Row 4 of Column 1 of Table 16: Change
R,S,S,-Thiomorpholine derivativec
to:
S,R,R,-Thiomorpholine derivativec
<659> PACKAGING AND STORAGE REQUIREMENTS GENERAL DEFINITIONS USP37–NF32 315 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Single-Dose (see also Injections <1>, Containers for Injections): Change
A single-unit package for an article intended for parenteral administration. Examples of single-dose containers include prefilled syringes, cartridges, fusion-sealed containers, and closure-… Read More
<1788> METHODS FOR THE DETERMINATION OF PARTICULATE MATTER IN INJECTIONS AND OPHTHALMIC SOLUTIONS LIGHT OBSCURATION PARTICLE COUNT TEST/Instrument Standardization Tests/Particle Counting Accuracy—System Suitability USP37–NF32 1301 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Line 11 of Method 2—Multichannel Instruments: Change
NMT ±10% of stated size.
to:
NMT ±10% of stated concentration.
CEFADROXIL FOR ORAL SUSPENSION IDENTIFICATION/Thin-Layer Chromatography/Chromatographic system USP37–NF32 2182 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Line 2 of Developing solvent system: Change
(60:40:15)
to:
(60: 40: 1.5)
CEFUROXIME AXETIL FOR ORAL SUSPENSION ASSAY/Procedure USP37–NF32 2243 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Change
Buffer: 23 mg/mL of monobasic ammonium phosphate in water
to:
Solution A: 23 g/L of monobasic ammonium phosphate in water
AND
Line 4 of System suitability solution: Change
Dilute with Buffer to volume.
to:
Dilute with Solution A to… Read More
DOLASETRON MESYLATE CHEMICAL INFORMATION USP37–NF32 2693 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Line 7: Change
[115956-13-3].
to:
[878143-33-0]
Anhydrous [115956-13-3].
FLUDARABINE PHOSPHATE IMPURITIES/Limit of Sodium USP37–NF32 3003 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Standard solution: Change
1 µg/mL of sodium chloride in water
to:
1 µg/mL of sodium in water
FLUTAMIDE ASSAY/Procedure USP37–NF32 3057 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Line 2 of Sample solution: Change
Dissolve the sample in acetonitrile
to:
Dissolve a previously dried sample in acetonitrile
LAMIVUDINE AND ZIDOVUDINE TABLETS IMPURITIES/Organic Impurities USP37–NF32 3484 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Row 17 of Column 1 of Table 2: Change
(the limit includes individual unidentified impurities)
to:
(the limit includes individual unspecified impurities)
MANNITOL INJECTION Assay USP37–NF32 3653 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Change:
Mobile phase, Resolution solution, and Chromatographic system—Proceed as directed in the Assay under Mannitol.
to:
Mobile phase—Use degassed water.
Resolution solution—Dissolve sorbitol and USP Mannitol RS in water to obtain a… Read More
METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS PERFORMANCE TESTS/Dissolution <711> USP37–NF32 3732 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Equation in Test 1: Change
Result = [(AU/AS) × CS × (VVS) + (C60 ×VS) + (C180 ×VS) ×100]/L
to:
Result = [(AU… Read More
MINOCYCLINE FOR INJECTION IMPURITIES USP37–NF32 3843 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Line 6 of Limit of Epiminocycline: Change
[Note—The relative retention times for epiminocycline and minocycline are 0.86 and 1.0, respectively.]
to:
[Note—The relative retention times for epiminocycline and minocycline are 0.7 and 1.0, respectively.]
PETROLATUM IMPURITIES/Organic Impurities/Procedure: Organic Acids USP37–NF32 4253 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Sample solution: Change
20.0 g of Petrolatum in 100 mL of neutralized alcohol and water (1:2).
to:
20.0 g of Petrolatum in 100 mL of a 1 in 2 mixture of neutralized alcohol and water.
WHITE PETROLATUM IMPURITIES/Organic Impurities/Procedure: Organic Acids USP37–NF32 4254 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Sample solution: Change
20.0 g in 100 mL of neutralized alcohol and water (1:2).
to:
20.0 g of White Petrolatum in 100 mL of a 1 in 2 mixture of neutralized alcohol and water.
SACCHARIN SODIUM IDENTIFICATION/B. Procedure USP37–NF32 4638 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Analysis: Change
To the Sample solution
to:
To 10 mL of the Sample solution
SACCHARIN SODIUM IMPURITIES/Organic Impurities/Procedure 1: Limit of Toluenesulfonamides USP37–NF32 4638 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Line 4 of Acceptance criteria: Change
of the Internal standard solution
to:
of the caffeine (internal standard)
SULFAMETHOXAZOLE AND TRIMETHOPRIM INJECTION ASSAY/Procedure USP37–NF32 4784 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Line 3 of Standard solution: Change
in Mobile phase from Sample stock solution
to:
in Mobile phase from Standard stock solution
SULFAMETHOXAZOLE AND TRIMETHOPRIM ORAL SUSPENSION ASSAY/Procedure USP37–NF32 4785 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Line 3 of Standard solution: Change
in Mobile phase from Sample stock solution
to:
in Mobile phase from Standard stock solution
SULFAMETHOXAZOLE AND TRIMETHOPRIM TABLETS ASSAY/Procedure USP37–NF32 4787 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Line 3 of Standard solution: Change
in Mobile phase from Sample stock solution
to:
in Mobile phase from Standard stock solution
ZANAMIVIR ASSAY/Procedure/Chromatographic system USP37–NF32 5197 1-Dec-2014 USP39–NF34 Second Supplement to USP38–NF33 Line 1 of Column: Change
5-μm packing L##1
to:
5-μm packing L82
AND
Delete footnote 1